Company Overview and News


Add PDLI
to your dashboard

Headline News

Neos Therapeutics: Third-Quarter Results Point To Upside

2017-11-20 seekingalpha
PDL BioPharma´s unsolicited offer is a clear indicator of the value to be found here going forward. (62-1)

Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles

2017-11-16 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (381-4)

NEOS Is Poised To Take Advantage Of Missteps By Pfizer And Noven

2017-11-16 seekingalpha
NEOS may be able to take advantage of these issues and build Cotempla market share faster than anticipated. (68-0)

Synergy Pharmaceuticals: How To Destroy Shareholder Value

2017-11-15 seekingalpha
It takes more than have a successful best of breed drug and beating quarterly estimates to succeed in the small biopharma space. (327-2)

AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

2017-11-13 zacks
AstraZeneca, plc (AZN - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending marketing approval of its respiratory disease candidate, benralizumab. AstraZeneca is looking to get benralizumab approved as an add-on maintenance treatment for severe eosinophilic asthma in adults. (56-0)

Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

2017-11-10 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) reported a loss of $2.07 in the third quarter of 2017, much narrower than the Zacks Consensus Estimate of a loss of $3.46. The company had reported a loss of $2.02 in the third quarter of 2016. (29-0)

Neos' (NEOS) CEO Vipin Garg on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Thank you for holding. Good morning. And welcome to Neos Therapeutics’ Third Quarter 2017 Financial Results Conference Call. Today’s call is being recorded. At this time, all participants are in a listen-only-mode. There will be a question-and-answer session to follow. (62-0)

Biotech Forum Daily Digest: Why Adamas Is Soaring

2017-11-06 seekingalpha
Biotech had a nice rally on Friday, which allowed the main biotech indices to post a slight gain on the week. (138-1)

PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

2017-11-04 zacks
PDL BioPharma, Inc. (PDLI - Free Report) reported earnings of 14 cents per share in the third quarter of 2017, surpassing the Zacks Consensus Estimate of 13 cents. The bottom line was also higher than the year-ago figure of 8 cents. (228-0)

PDL BioPharma's (PDLI) CEO John McLaughlin on Q3 2017 Results - Earnings Call Transcript

2017-11-03 seekingalpha
Good afternoon and welcome to PDL BioPharma's Third Quarter 2017 Earnings Call. Today's call is being recorded. For opening remarks and introductions, I would now like to turn the call over to Jennifer Williams. (64-1)

BRIEF-PDL Biopharma Inc reports Q3 revenue $62.7 million

2017-11-02 reuters
* PDL Biopharma Inc - ‍qtrly GAAP diluted EPS of $0.14​ Source text for Eikon: Further company coverage: (10-1)

PDL BioPharma, Inc. to Host Earnings Call

2017-11-02 accesswire
(10-1)

Magic Formula Investing Companies Vs. The Most Traded Companies In The U.S. Markets

2017-11-01 seekingalpha
Explanation of what the Greenblatt Magic Formula is all about, and how the system works. The historical background is also explained. (1741-5)

PDL BioPharma And Neos Therapeutics - The Deal That Could Have Been

2017-11-01 seekingalpha
For the past year, PDLI mgmt. has stated they plan on making an equity pharma offer. (62-0)

Neos Therapeutics to consider other offers after PDL snub -sources

2017-10-31 reuters
(Reuters) - U.S. drugmaker Neos Therapeutics Inc, which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter. (62-0)

CUSIP: 69329Y104